Key result
Subcutaneous application of copper-histidine (Cu-his) was the most likely explanation for the resolution of severe hypertrophic cardiomyopathy in a patient with SCO 2 mutations.
Why the study?
Does subcutaneous copper-histidine improve cardiac function in a patient with SCO2 mutation-associated hypertrophic cardiomyopathy?
Case Report (n=1)
Does subcutaneous copper-histidine improve cardiac function in a patient with SCO2 mutation-associated hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Subcutaneous copper-histidine supplementation may reverse severe hypertrophic cardiomyopathy in patients with SCO2 mutations.
Mutations in Sco2, a protein involved in copper trafficking to the terminal enzyme of the respiratory chain, cytochrome c oxidase, results in infantile hypertrophic cardioencephalomyopathy. We have recently shown that copper-histidine (Cu-his) supplementation of Sco2-deficient myoblasts rescues COX activity in vitro. Here, we report a patient with SCO 2 mutations and with resolution of severe hypertrophic cardiomyopathy. Weighing up the evidence, the most likely explanation for the improved cardiac function in this patient was the subcutaneous application of Cu-his.
No takes yet. Share an insight, caveat, or question.
Freisinger et al. (2004) conducted a case report in Infantile hypertrophic cardioencephalomyopathy with SCO 2 mutations (n=1). Subcutaneous copper-histidine (Cu-his) was evaluated on Resolution of severe hypertrophic cardiomyopathy. Subcutaneous application of copper-histidine (Cu-his) was the most likely explanation for the resolution of severe hypertrophic cardiomyopathy in a patient with SCO 2 mutations.
Synapse has enriched 10 related papers. Consider them for comparative context: